Evidence map›Paper›PMID 24185710›Full record

ArticleCellular & molecular immunology2014

Activation of the Ig Iα1 promoter by the transcription factor Ets-1 triggers Ig Iα1-Cα1 germline transcription in epithelial cancer cells.

Zhi Duan, Hui Zheng, San Xu, Yiqun Jiang, Haidan Liu, Ming Li, Duosha Hu, Wei Li, Ann M Bode, Zigang Dong and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular & molecular immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Comparison of Non B-Ig and B-Ig.Advances in experimental medicine and biology · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Distinct peripheral blood monocyte and neutrophil transcriptional programs following intracerebral hemorrhage and different etiologies of ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Zhi Duan1] Laboratory of Tumor Molecular Biology, Cancer Research Institute, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.
Hui Zheng1] Laboratory of Tumor Molecular Biology, Cancer Research Institute, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.
San Xu1] Laboratory of Tumor Molecular Biology, Cancer Research Institute, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.
Yiqun Jiang1] Laboratory of Tumor Molecular Biology, Cancer Research Institute, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.
Haidan LiuCenter of Clinical Gene Diagnosis and Therapy, Department of Cardiothoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Ming LiDepartment of Immunology, Xiangya Medical College, Central South University, Changsha, China.
Duosha Hu1] Laboratory of Tumor Molecular Biology, Cancer Research Institute, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.
Wei Li1] Laboratory of Tumor Molecular Biology, Cancer Research Institute, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China [4] The Hormel Institute, University of Minnesota, Austin, MN, USA.
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, MN, USA.
Zigang DongThe Hormel Institute, University of Minnesota, Austin, MN, USA.
Ya Cao1] Laboratory of Tumor Molecular Biology, Cancer Research Institute, Central South University, Changsha, China [2] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, China [3] Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, China.
Central South University · CNUniversity of Minnesota · USMinistry of Education of the People's Republic of China · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulins (Igs) are known to be synthesized and secreted only by B lymphocytes. Class switch recombination (CSR) is a key event that enables B cells to express Igs, and one of the crucial steps for CSR initiation is the germline transcription of Ig genes. Surprisingly, recent studies have demonstrated that the Ig genes are also expressed in some epithelial cancer cells; however, the mechanisms underlying how cancer cells initiate CSR and express Igs are still unknown. In this study, we confirmed that the Ig Iα1 promoter in cancer cell lines was activated by the Ets-1 transcription factor, and the activity of the Ig Iα1 promoter and Ig Iα1-Cα1 germline transcription were attenuated after knockdown of Ets-1 by specific small interfering RNAs (siRNA). Furthermore, the expression of Ets-1 and Igα heavy chain in cancer cells was dose dependently upregulated by TGF-β1. These results indicate that activation of the Ig Iα1 promoter by the transcription factor Ets-1 is a critical pathway and provides a novel mechanism for Ig expression in non-B cell cancers.

Indexed as

CarcinomaEpithelial CellsGene Expression Regulation, NeoplasticHeLa CellsHumansImmunoglobulin AImmunoglobulin alpha-ChainsImmunoglobulin Constant RegionsOrgan SpecificityPromoter Regions, GeneticProto-Oncogene Protein c-ets-1RNA, Small InterferingTranscriptional ActivationTransforming Growth Factor beta1Up-RegulationETS1 protein, humanImmunoglobulin AImmunoglobulin alpha-ChainsImmunoglobulin Constant RegionsProto-Oncogene Protein c-ets-1RNA, Small InterferingTransforming Growth Factor beta1

Identifiers

PMID24185710
PMCPMC4003374
OpenAlexW2038647408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.